Scarica l'app Stockscreener
14.88
2.04%
-0.31
Dopo l'orario di chiusura:
14.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.19
Aprire:
$15.21
Volume 24 ore:
1.37M
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.52B
Reddito:
$70.85M
Utile/perdita netta:
$-324.22M
Rapporto P/E:
-3.9091
EPS:
-3.8065
Flusso di cassa netto:
$-277.36M
1 W Prestazione:
+2.83%
1M Prestazione:
-48.12%
6M Prestazione:
-33.18%
1 anno Prestazione:
+16.25%
Intervallo 1D:
$14.76
$15.34
Intervallo di 1 settimana:
$14.35
$15.58
Portata 52W:
$11.76
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
14.88 | 1.55B | 70.85M | -324.22M | -277.36M | -3.8065 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Sectors Review: Is Viridian Therapeutics Inc undervalued by DCF analysisGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Portfolio Recap: Will Viridian Therapeutics Inc outperform its industry peersQuarterly Trade Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (VRDN) Movement - Stock Traders Daily
Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN
Why is Viridian Therapeutics stock sinking Monday? - MSN
Viridian Therapeutics (VRDN) Is Down 18.4% After Strong REVEAL-1 Elegrobart TED DataWhat's Changed - Sahm
Options Flow: Can Viridian Therapeutics Inc beat the S P 500Weekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics price target lowered to $36 from $40 at Truist - Yahoo Finance
Why is Viridian Therapeutics stock falling Monday? - MSN
Stock Market Recap: Can Viridian Therapeutics Inc stock double in the next yearBreakout Watch & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi‑Month Share Price Pullback - Yahoo Finance
Goldman Sachs Maintains Buy Rating on VRDN, Lowers Price Target - GuruFocus
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail
VRDN: RBC Capital Lowers Price Target on Viridian Therapeutics | - GuruFocus
H.C. Wainwright reiterates Viridian stock rating citing trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Viridian stock rating citing trial data - Investing.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
RBC Cuts Price Target on Viridian Therapeutics to $30 From $42, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital cuts Viridian Therapeutic stock price target on competition By Investing.com - Investing.com Canada
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's
Viridian Therapeutics stock tumbles after Amgen Tepezza data By Investing.com - Investing.com Australia
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
Leerink reiterates Viridian Therapeutic stock rating after rival data By Investing.com - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Latest Stock News & Headlines - Yahoo Finance
Viridian Therapeutics (VRDN) Shares Drop Amid Competitor's Trial Success - GuruFocus
Viridian Therapeutic stock maintained at Outperform by RBC Capital - Investing.com Canada
Why Is Viridian Therapeutics Stock Sinking Monday?Amgen (NASDAQ:AMGN), Viridian Therapeutics (NASDAQ:V - Benzinga
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well - Moomoo
Viridian Therapeutics (NASDAQ:VRDN) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Best Biotech Stocks To ConsiderApril 6th - MarketBeat
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics (VRDN) slides 26.8% as investors digest Phase 3 REVEAL-1 data and reset expectations - Quiver Quantitative
Institution Moves: Is Viridian Therapeutics Inc subject to activist investor interestWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Earnings Report: Should I hold or sell Viridian Therapeutics Inc nowForecast Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $48 - Moomoo
VRDN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart DataWhat's Changed - Sahm
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):